INCY: Summary for Incyte Corporation - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 2:38pm EST - Canadian Markets close in 1 hour and 22 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Incyte Corporation (INCY)

At 14:23 EST: 8.55 USD

0.83 (10.75%)

MORE ON INCY

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Incyte Corporation (NGM:INCY) Delayed quote data

Last Trade:	8.55 USD
Trade Time:	2:23PM EST
Change:	0.83 (10.75%)
Prev Close:	7.72
Open:	8.40
Bid:	8.54 x 5000
Ask:	8.55 x 700
1y Target Est:	14.33

Day's Range:	7.98 - 8.64
52wk Range:	1.96 - 8.32
Volume:	20,079,009
Avg Vol (3m):	2,926,230
Market Cap:	1.01B
P/E (ttm):	N/A
EPS (ttm):	-1.02
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add INCY to Portfolio

Download Data

HEADLINES

•	Biotech Stocks: Incyte, Idera move on Novartis deals
	at MarketWatch (Wed 2:02pm)

•	Wall Street lifted by data and dollar
	at FT.com (Wed 1:50pm)

•	Tiny Incyte Gets Boost From Novartis Deal
	at Minyanville.com (Wed 12:45pm)

•	Incyte shares rally on Novartis deal
	at MarketWatch (Wed 12:28pm)

•	Novartis Deal Gives Incyte a Boost
	at Seeking Alpha (Wed 12:07pm)

•	Incyte could get $1.3B from Novartis in team-up
	AP (Wed 10:53am)

•	UPDATE - Novartis strikes licensing deal with Incyte
	at Reuters (Wed 10:29am)

•	Incyte, Sequenom: Early Volume Plays
	at TheStreet.com (Wed 9:23am)

•	European Factors -- Shares set to open higher, data eyed
	at Reuters (Wed 2:48am)

•	Incyte to license 2 hematology drugs to Novartis
	at MarketWatch (Wed 2:28am)

•	Incyte Announces Major Collaboration and License Agreement for Two Hematology-Oncology Programs
	Business Wire (Wed 1:15am)

More Headlines for INCY...

ANALYST

EPS Est (next year) (Dec-07) :	-1.06
EPS Est (in 2 years) (Dec-08) :	-1.39
Avg Rec (current)*:	2.3
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Incyte Corporation is a drug discovery and development company, which focuses on developing proprietary small molecule drugs to treat human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases.

Full Company Profile

Add to Portfolio

Email to a Friend

•